Search Results

Your search for Robert Peter Gale, MD, PhD, DSc(hc), FACP, FRCP, FRCPI(hon), FRSM matches 2 pages

Showing 1 - 2

By Robert Peter Gale, MD, PhD, DSc(hc), FACP, FRCP, FRCPI(hon), FRSM; Rüdiger Hehlmann, MD, PhD; and Andreas Hochhaus, MD / March 25, 2020

AML Pioneer and Giant, Clara D. Bloomfield, MD, FASCO, Dies at 77

Physicians and scientists interested in acute myeloid leukemia (AML) have lost one of the community’s shining lights with the death of Clara D. Bloomfield, MD, FASCO, on March 1, 2020, at age 77 years. Dr. Bloomfield is well known for her more than 50 years of groundbreaking research in blood...

issues in oncology

By Robert Peter Gale, MD, PhD, DSc(hc), FACP, FRCP, FRCPI(hon), FRSM, and David G. Nathan, MD / July 25, 2019

Physicians and the Threat of Nuclear War

The Hippocratic Oath calls on physicians to “use treatment to help the sick according to my ability and judgment,” but not all versions of the oath call on us to prevent disease. Here we urge our colleagues to acknowledge that additional mandate and renew their commitment to preventing what could ...

Nov

Today In Oncology

Search Results

Your search for Robert Peter Gale, MD, PhD, DSc(hc), FACP, FRCP, FRCPI(hon), FRSM matches 2 pages

AML Pioneer and Giant, Clara D. Bloomfield, MD, FASCO, Dies at 77

Physicians and the Threat of Nuclear War

Firefighters May Be Exposed to Chemicals Associated With Breast Cancer

FDA Grants Accelerated Approval to Zanidatamab-hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer

Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC

Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System

Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma